Let's get the data we're missing, which I believe will explain that 50 or more survived beyond 7 years, then better adjectives can be selected. Meanwhile, in many cancer trials the goal is to exceed the existing SOC by 10 to 20% to gain approval. We have more than doubled the number of long term survivors with just the data we have. I know it's only expanding 5 year survival from 5% to over 10%, but I believe that's far better than just good results.
Clearly Dr. Liau wouldn't stop working on curing GBM based on this, but she wouldn't stop if we were curing 50% either. I think it's clear that Keytruda provides a benefit, but only if accompanied by DCVax-L, no telling what other drugs which previously failed in GBM without DCVax-L may provide further benefits when used with it.
Once DCVax-L is approved many developers of successful drugs that previously failed with GBM may be looking at trials where they'll pay NWBO for the vaccine they'll be using. I know people think Merck has the inside track, but even if NWBO partnered, or were acquired by Merck I don't believe they'd deny someone else paying to use DCVax-L in a trial that would potentially expand its use, whether it's in GBM or other cancers.
Let's see what news tomorrow brings, but I really don't believe that we have anything to be ashamed about, it's better than just good.
Gary
News 
Market Data 
Discover 
